Description

Tilmicosin is a broad-spectrum semi-synthetic bactericidal macrolide antibiotic synthesized from Tylosin. It has an antibacterial spectrum that is predominantly effective against Mycoplasma, Pasteurella and Haemophilus spp. and various Gram-positive organisms such as Corynebacterium spp. It is believed to affect bacterial protein synthesis through binding to 50S ribosomal subunits. Cross-resistance between tilmicosin and other macrolide antibiotics has been observed. Following oral administration, tilmicosin is excreted mainly via the bile into the faeces, with a small proportion being excreted via the urine.